Statistics

Total Visits

Views
Long-term progression-free-survival (PFS) under sunitinib (SU) treatment for metastatic renal cell carcinoma (Sulong study): Analysis of two populations - long term responders (LR) vs. primary refractory (PR) patients38

Select a period of time:

Number of views in the range

Views
Long-term progression-free-survival (PFS) under sunitinib (SU) treatment for metastatic renal cell carcinoma (Sulong study): Analysis of two populations - long term responders (LR) vs. primary refractory (PR) patients29

Views

Views
January 20258
February 20250
March 202516
April 20252
May 20252
June 20251
July 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore16
United States5
United Kingdom5
Lithuania2
Spain1
 

Top cities views

Views
Charlotte2
Cleveland1
Council Bluffs1
Glasgow1